Introduction {#Sec1}
============

Porcine reproductive and respiratory virus (PRRSV) is the etiological agent of one of the most important swine diseases with a significant economic burden worldwide. Only in the US, it is estimated that \$560 million yearly losses are directly related to this disease \[[@CR1]\]. Current vaccines against PRRSV have focused on methods using modified live or attenuated virus \[[@CR2]\], peptides \[[@CR3]\], vectored vaccines \[[@CR4]\], inactivated virus and subunit vaccines \[[@CR5]--[@CR7]\]. Available vaccines, however, have limitations such as little protective immunity \[[@CR8]\], possible reversion to virulence \[[@CR9]\], and incapability of eliciting long lasting and heterologous protection among European and American genotypes \[[@CR10]\]. In addition, PRRSV strains have high antigenic variability and genetic polymorphisms \[[@CR11], [@CR12]\] and the highest mutation rate of RNA viruses \[[@CR5]\]. All together, these limitations indicate that new alternatives to conventional vaccines are desperately needed aiming to control and eventually eradicating PRRSV.

Exosomes are 30--100 nm vesicles of endocytic origin originally described as a "garbage-disposable" mechanism of reticulocytes in their terminal differentiation to erythrocytes \[[@CR13], [@CR14]\]. This cellular origin and function were shown not to be unique as 10 years later, B-cells were also described to secrete exosomes with antigen presentation capacity and with the ability of generating specific T-cell responses \[[@CR15]\]. Since these seminal observations, exosomes have been shown to be secreted by all immune cells and explored as novel vaccination approaches \[[@CR16]\]. In fact, proof-of-principle Phase I clinical trials using dendritic cell-derived exosomes coupled to tumor-associated antigens have shown their safety and immunogenicity in cancer and Phase II trials are presently being conducted \[[@CR17]\]. Of interest, antigens from infectious diseases associated with exosomes also demonstrated their capacity for eliciting specific and protective immune responses in preclinical mouse models \[[@CR18]--[@CR20]\]. For instance, vaccination with extracellular vesicles and exosomes can induce a strong immune response and increase survival in *Mycobacterium tuberculosis*, *Eimeria tenella*, *Toxoplasma gondii* \[[@CR18], [@CR19]\] and full protection against a lethal challenge in *Plasmodium yoelii* experimental infections \[[@CR21]\]. Moreover, outer membrane vesicles (OMVs) derived from *Bordetella pertussis* used as vaccine in mice ameliorated infection following challenge with several strains \[[@CR20]\]. For virus, exosomes play an important role not only involved in pathogenesis and virus spreading \[[@CR22]\] but also in cell communication and protection against infection \[[@CR23]\]. All together, these data strongly suggest the value of exosomes as a new vaccination approach in human health. Yet, no reports have shown their potential value for vaccination in animal health.

In this work, we describe the isolation and molecular composition of serum-derived exosomes obtained from naïve pigs, from viremic animals and from non-viremic animals previously infected with PRRSV. Our results unequivocally identified viral antigens associated to exosomes in viremic and non-viremic pigs. Moreover, viral proteins contained in serum-derived exosomes from non-viremic animals exhibit antigenic potential as judged by ELISA assays. A scaling-up protocol for obtaining serum-derived exosomes was also developed. Thus, opening the possibility of exploring these non-viremic nanovesicles as a novel vaccination approach against PRRSV.

Materials and methods {#Sec2}
=====================

Samples {#Sec3}
-------

Sera were obtained from large white X Landrace pigs of approximately seventeen weeks of age that had suffered a PRRSV natural outbreak in two conventional farms and from animals of one PRRSV negative farm (naive pigs). The two PRRSV positive farms belong to the same integration company but from different sow origin. The PRRSV negative farm pertains to a different integration Company; thus, avoiding any confounding with samples. Viral as well as serological status of animals against PRRSV antigens were analyzed, respectively, by RT-PCR TaqMan® NA/EU PRRSV Reagents (Applied Biosystems) and IDEXX PRRS X3 Antibody Test (IDEXX). An independent diagnostics laboratory for porcine diseases in Lleida \[[@CR24]\] confirmed these analyses following their own standard operational procedures.

Sera from all animals were classified as non-viremic (NV, PRRSV negative by RT-PCR) or viremic (V, PRRSV positive by RT-PCR), being both groups serologically positive to PRRSV using an IDEXX PRRS X3 Antibody Test. On the other hand, sera from naive control animals (CN) were PRRSV negative and free from antibodies against PRRSV. Details of sera used in this study are included in Additional file [1](#MOESM1){ref-type="media"}. All studies were approved by the ethical committee of the University of Lleida, Spain, and performed under their guidelines for animal care (DAAM7684).

Exosome isolation: size-exclusion chromatography {#Sec4}
------------------------------------------------

Isolation of serum-derived exosomes by size exclusion chromatography (SEC) were performed as previously described \[[@CR25]\]. Briefly, Sepharose CL-2B (Sigma-Aldrich, St. Louis, MO, USA) was packed in 10 mL syringes to a final volume of 10 mL and equilibrated with PBS-Citrate 0.32% (w/v). Frozen serum samples were thawed on ice, centrifuged at 500×*g* for 10 min at room temperature to remove cellular debris, and 2 mL aliquots were applied to each column. Collection of 20 fractions of 0.5 mL each started immediately using PBS-citrate as the elution buffer. Protein content of each fraction was analyzed using Bradford protein quantification assay according to manufacturer's instructions (Bradford reagent, Sigma-Aldrich). To determine protein profiles, samples were loaded into 10% polyacrylamide BIORAD precast gels, separated at 120 V for 45 min and stained using SilverQuestTM Staining kit (Invitrogen).

Flow cytometry analysis of molecular markers associated with extracellular vesicles {#Sec5}
-----------------------------------------------------------------------------------

A bead-based assay for detection of two classical exosome markers, CD63 and CD81 was used to phenotypically identify SEC fractions containing exosomes \[[@CR26]\]. Briefly, exosomes were coupled with Aldehyde/Sulfate Latex Beads, 4% w/v, 4 µm (Invitrogen) and then blocked with PBS 1X/BSA 0.1% (Sigma-Aldrich) /NaN3 0.01% (Sigma-Aldrich). Fractions were incubated in microtest conical bottom 96-well plates for 30 min at 4 °C with anti-CD63 and anti-CD81 antibodies (culture supernatant monoclonal antibodies) at 1:10 dilution. After washing, a 1/100 dilution of secondary antibody FITC (Southern Biotech) was incubated for 30 min at 4 °C. After removal of unbound secondary antibodies by centrifugation, beads were suspended in PBS and analyzed by flow cytometry using aBD FACSVerse (BD Biosciences) equipment. Median Fluorescence Intensity (MFI) and beads count data were obtained by FlowJo analysis Software of every sample-reading file.

Nanoparticle tracking analysis (NTA) {#Sec6}
------------------------------------

Diameter size and concentration of vesicle population was determined using NanoSight LM10 equipment (Malvern). Fractions were evaluated using different dilutions in sterile-filtered PBS 1X (1/10 to 1/50) and the following parameters: camera at 30 frames per second (FPS), camera level at 16, temperature between 21--25 °C and video recording time 60 s in order to estimate the concentration and size distribution of vesicle population through light scattering and Brownian motion. Nanosight NTA Software analyzed raw data videos by triplicate and results were obtained in PDF datasheet with all selected values (Mean size, Median size, Mode size and concentration).

Cryo-electron microscopy (Cryo-TEM) {#Sec7}
-----------------------------------

Ten microliter aliquots from individual SEC fractions containing exosomes were directly laid on Formvar-Carbon EM grids and frozen in ethanol. Samples were analyzed on a Jeol JEM 2011 transmission electron microscope at an accelerating voltage of 200 kV. Samples and the 626 Gatan cryoholder were maintained at −182 °C during the whole process. To minimize electron bean radiation, images were recorded on a Gatan Ultrascan cooled CCD camera under low electron dose conditions. Vesicle size was determined using the ImageJ software (NIH) and setting calibration was performed pixels/nanometer.

Mass spectrometry {#Sec8}
-----------------

Liquid Chromatography (nanoLCULTRA-EKSIGENT) followed by mass spectrometry (nanoLC-MS/MS) was performed on a LTQ Orbitrap Velos (Thermo Fisher). Briefly, samples were reduced with 10 mM DTT (Dithiothreitol), alkylated with 55 mM iodoacetamide and precipitated by 10% TCA. After washing with acetone, 2 μL of 8 M urea were added and samples brought to a final concentration of 1.6 M urea. One microgram of trypsin (*Sus scrofa*) was added and digestions were carried overnight at 37 °C. The reaction was stopped with 1% formic acid. The amount of sample submitted to mass spectrometry analyses was based on nanoparticle tracking analysis (see below) and ranged from 9.8 × 10^7^ to 3.9 × 10^8^ particles/mL among all samples analyzed. MS/MS was performed in the LTQ using data dependent dynamic exclusion of the top 20 most intense peptides using repeat count = 1, repeat duration = 30 s, exclusion list size of 500 and exclusion list duration = 30 s as a parameters. The top 20 most intense peptides were isolated and fragmented by low energy CID, 35% collision energy.

Database search and protein identification {#Sec9}
------------------------------------------

Raw spectral data from Xcalibur™ (Thermo Scientific, v2.1) was searched against a custom database compiled from \[[@CR27]\] in FASTA format for uploading it into Andromeda Search Engine 1.4. The database contained complete and partial sequences of PRRSV (22 976 sequences) and *Sus scrofa* (59 898 sequences). The sequence for trypsin from *Sus scrofa* (Accession P00761 from \[[@CR28]\]) and default contaminant database were also included in the search carried out with Maxquant 1.5/Andromeda 1.4 software. Contaminants and proteins identified only by site modification were filtered out from the list. Proteins found in all groups were scored positive if they had at least two unique peptides and 1% False Discovery Rate (FDR) for protein and peptide identification. After filtering, proteins of each group were compared in a Venn diagram using Venny 2.0 software \[[@CR29]\] to determine which proteins were unique and shared among samples.

Gene ontology (GO) analyses by PANTHER overrepresentation test {#Sec10}
--------------------------------------------------------------

Porcine proteins identified by Maxquant 1.5/Andromeda 1.4 Software were filtered by elimination of "contaminants" and "Only identified by site proteins". Then, the most common proteins with highest score were summited to UniprotKb "retrieve/ ID mapping \[[@CR28]\] to convert GI numbers (Maxquant results) to UniprotKB ID number and eliminating redundant hits. Then, the final protein list (184) (.tab format) was summited to PANTHER Overrepresentation Test (release 20150430) \[[@CR30]\] using Annotation Version: PANTHER version 10.0 Released 2015-05-15, Reference List: *Sus scrofa* (all genes in database) and perform all three GO-Slim analysis available (Biological process, Cellular component and Molecular function) \[[@CR31]\]. Also, exosomal proteins of *Sus scrofa* were compared against exosome proteins of different farm animals (*Bos taurus*, *Equus caballus*, *Gallus gallus* and *Rattus norvegicus*) using Funrich analysis software \[[@CR32]\].

ELISA assays {#Sec11}
------------

An indirect ELISA protocol was initially performed (dilution chessboard) for titration of sera coming from NV, V and CN pigs using a secondary antibody Goat anti-Pig IgG (Fc): HRP (AbSerotec AAI41P) and Porcillis PRRSV vaccine as coating antigen (Intervet Lot. A200ED03) (Additional file [2](#MOESM2){ref-type="media"}). Using a range of sera dilutions previously titrated, circulating IgG antibodies from NV and CN pigs were tested in a double ELISA test against homologous NV serum-derived exosomes (sandwich ELISA) and against whole viral vaccine (Porcillis PRRS Vaccine "intervet" lot. A200ED03) as previously described. For sandwich ELISAs, plates were first coated with anti-CD63 antibodies and after washing and blocking, SEC fractions (100 uL per well) containing exosomes were incubated 90 min at 37 °C. Sera samples were afterwards incubated for 1 h at room temperature, washed and incubated with secondary antibody Goat anti-Pig IgG (Fc): HRP (AbSerotec AAI41P) at 1:10 000 dilution and optical density was measured at 450 nm using Varioskan equipment (Thermo Scientific).

Scaling-up process for vesicle enrichment and isolation {#Sec12}
-------------------------------------------------------

The process of polyethylene-glycol (PEG) precipitation was based on scale-up process for retrovirus stock in order to maintain structure and functionality of extracellular vesicles \[[@CR33], [@CR34]\]. Thus, two adult healthy animals (80--100 kg) were anesthetized and approximately 500 mLs of peripheral blood from each animal collected by venous puncture. Blood was collected into 50 mL Falcon tubes to facilitate collection of sera and minimize hemolysis. Sera were precipitated overnight at room temperature by adding PEG at 8.5% w/v ratio. Pellets were resuspended in 20 mLs of PBS and loaded into PuriFlash Dry Load Columns 80G (Interchim) filled with 100 mL of sepharose CL-2B (separation matrix) and 5 mLs fractions collected for further analysis.

Results {#Sec13}
=======

Characterization of serum-derived exosomes after purification by size exclusion chromatography {#Sec14}
----------------------------------------------------------------------------------------------

SEC was used to isolate exosomes from sera of naïve animals (CN) pertaining to a PRRSV negative farm, and sera from viremic animals (V) or non-viremic (NV) animals from two PRRSV positive farms where different PRRS viruses were detected. Preliminary studies on sequence polymorphisms from PRRSV viruses isolated in these farms revealed 85% homology among them (data not shown). Twenty 0.5 mL aliquot fractions were collected from each serum and individually analysed for (i) for their protein content and (ii) for the presence of two "classical" exosome markers, CD63 and CD81. In all samples analysed, exosome markers were identified in fractions 7--10, whereas total protein content increased in later fractions (Figure [1](#Fig1){ref-type="fig"}A). In addition, NTA revealed that preparations from all animals were highly homogeneous in terms of particle size (100--200 nm with a medium size of 127 nm) and concentration (10^9^--10^10^ particles per mL) (Figure [1](#Fig1){ref-type="fig"}B; Additional file [3](#MOESM3){ref-type="media"}). Furthermore, electrophoresis of the protein content of SEC fractions from different samples revealed a similar profile in early fractions and, as expected, an enrichment of plasma proteins in late fractions (Figure [1](#Fig1){ref-type="fig"}C). Vesicle size and structure were also analysed by cryo-TEM. Similar to NTA, vesicles from 80--200 nm in diameter were predominantly observed whereas electro-dense bodies typically associated with viral particles, were not (Figure [1](#Fig1){ref-type="fig"}D).Figure 1**Characterization of porcine serum-derived exosomes sera by different methodologies.** Bradford and flow cytometry analyses (**A**), nanoparticle tracking analysis (**B**), cryo-electron microscopy (**C**) and SDS-PAGE/Silver Staining (**D**) are represented. MFI: Median fluorescence unit, mg/mL: Bradford measure unit, M: Molecular weight marker, F6-F9: Fraction number from SEC and percentage (%) size distribution (nm).

Proteomic analysis {#Sec15}
------------------

To characterize the exosome protein composition from different groups of animals, liquid chromatography and mass spectrometry were applied for protein sequencing and identification from samples of one NV animal and two V animals (Figure [2](#Fig2){ref-type="fig"}). Of importance, peptides pertaining to viral proteins were identified in serum-derived exosomes from all animals whereas others were uniquely identified. Thus, peptides from major envelope glycoprotein GP5-Tm:pFc (a fusion protein of GP5 with no transmembrane domain and pig fragment crystallizable portion), from envelope glycoprotein GP3, NSP2 and partial ORF2b were detected in exosomes from all (NV and V) animals. Other peptides from nucleocapsid protein, envelope glycoprotein GP3 protein, major envelope glycoprotein GP5 and replicase polyprotein 1ab, where only identified in exosomes from V animals whereas peptides from envelope glycoprotein 3 were identified in exosomes from one V and one NV animal. Interestingly, peptides from RNA-dependent RNA polymerase and nucleocapsid protein N, were detected only in exosomes from NV animals.Figure 2**Venn diagram showing overlap and unique peptides of viral proteins detected in different sample groups: non-viremic (201406-6PS) and viremic (201406-2PS and 201406-4PS).** The overlapping and unique peptides identified for proteins in these sample groups are shown.

To confirm the presence of unique viral proteins in exosomes from NV animals, three additional samples were also analysed by liquid chromatography and mass spectrometry and confirmed the presence of RNA-dependent RNA polymerase, partial and nucleocapsid protein N. None of these proteins were found in serum-derived exosomes from naïve animals (CN) further confirming the specificity of these results (not shown).

The proteomics analysis also identified more than 400 porcine proteins contained within exosomes (Additional file [4](#MOESM4){ref-type="media"}). Of interest, GO analysis showed an important enrichment of lipid transport, response to external stimulus, proteolysis, enzymatic activities and extracellular space proteins, all related to exosomes composition and function (Table [1](#Tab1){ref-type="table"}). Besides, when comparing exosome porcine proteins in our database with exosomes from other farm animals using the Funrich software \[[@CR32]\], 48 proteins were shared among *B. taurus* and *S. scrofa* (approximately 2.9% of total proteins), 5 with *E. caballus*, 6 with *G. gallus* and 3 with *R. norvegicus* as outlier in the evolutionary line (Additional file [5](#MOESM5){ref-type="media"}). Interestingly, even though the pig protein database is smaller than others in these analyses, there is a coincidence of 3% with *Bos taurus*, and at least 4 of these proteins are classical exosomal markers (CD5, CD9, CD81 and CD63) (Additional file [5](#MOESM5){ref-type="media"}).Table 1**Gene Onthology analysis of** ***Sus scrofa*** **proteins detected in exosomal enriched fractions**Ref list. 21483Exp. list (91)ExpectedOver/underFold enrichment*P* valuePANTHER GO-slim biological process Lipid transport305101.29+ \>51.67E−04 Response to external stimulus347101.47+ \>55.24E−04 Proteolysis690122.92+4.117.98E−03 Response to stress659112.79+3.942.48E−02 Immune system process1399175.93+2.871.65E−02 Localization26102811.06+2.534.69E−04 Transport24842610.52+2.471.93E−03 Response to stimulus23642310.01+2.32.31E−02 Unclassified93762439.72−0.60.00E+00PANTHER GO-slim molecular function Lipid transporter activity10680.45+\>53.51E−06 Peptidase inhibitor activity227100.96+\>58.65E−06 Serine-type peptidase activity293111.24+\>58.91E−06 Enzyme inhibitor activity337101.43+\>53.08E−04 Peptidase activity605162.56+\>59.26E−07 Receptor binding947184.01+4.491.42E−05 Hydrolase activity2181239.24+2.495.06E−03 Protein binding27292811.56+2.428.53E−04 Unclassified10 7943545.72−0.770.00E+00PANTHER GO-slim cellular component Extracellular space630.03+\>51.22E−04 Extracellular region624182.64+\>56.31E−09 Unclassified17 2956273.26−0.850.00E+00

Specific immune recognition of PRRSV-proteins in serum-derived exosomes {#Sec16}
-----------------------------------------------------------------------

To determine whether serum-derived exosomes from NV animals contained antigenic viral proteins, swine sera was tested by indirect and sandwich ELISA. First, sera was titrated using Porcilis PRRSV vaccine as coating antigen and showed maximum differences between CN and NV animals at 1/50--1/100 dilutions and 1/10 000 dilution of the secondary antibody without being at saturation values (Additional file [2](#MOESM2){ref-type="media"}). As shown in Figure [3](#Fig3){ref-type="fig"}, statistically significant differences (*p* \< 0.05) between sera from NV and CN animals using three individual NV exosome preparations (1PS, 2PS and 3PS) at 1/50 and 1/100 dilutions, were observed. Moreover, similar reactivity and statistical significance were observed when sera from CN and NV animals were tested against a commercially available vaccine (Porcillis PRRSV vaccine, Intervet) as the coating antigen. In addition, evaluation of antigenicity was done in concentrated exosome samples obtained through PEG/SEC isolation. Non-viremic sera but not naïve was able to recognize exosomes derived from non-viremic animals in a dose dependent manner (Figure [4](#Fig4){ref-type="fig"}).Figure 3**ELISA assay for evaluation of NV and CN porcine sera immune recognition over inactivated viral particle PRRSV vaccine (Porcilis PRRS, Intervet) and exosomes derived from NV porcine sera of different origin.** Analyses of naïve (CN) and non-viremic (NV) sera against exosomes derived from sample 201502-1PS (**A**), 201502-2PS (**B**) and 201502-3PS (**C**). Optical density (OD) was measured at 450 nm and it is represented in the "Y" axis. "X" axis shows the dilution factor for sera samples (1/50 to 1/400). For each animal, exosomes were isolated and captured using anti-CD63 antibody and tested against both sera (\*\**p* \< 0.01; \*\*\**p* \< 0.0001).Figure 4**Characterization of exosomes isolated using PEG/SEC methodology from porcine sera.** Bradford and flow cytometry analyses (**A**), Sandwich ELISA for exosomes derived from non-viremic animal (**B**), are represented. MFI: Median fluorescence unit, mg/mL: Bradford measure unit, CD63-CD81 are molecular markers for exosomes characterization. For FACS and Bradford analyses is evident that higher values are represented in comparison with non-concentrated samples (10-fold change). In addition, the indirect quantification through Bradford of protein associated with exosomes it is possible when sera is concentrated through PEG and separated using SEC, making this an important tool for further evaluation of immunogenic properties in vitro and in vivo. For the sandwich ELISA, exosomes derived from non-infected animal were tested against two types of porcine sera. Optical density (OD) was measured at 450 nm and represented in the "Y" axis. "X" axis shows the dilution factor for exosomes samples (1 to 1/200). Duplicated values are represented as squares and dots and mean as a line.

Scaling-up process for vesicle enrichment and isolation {#Sec17}
-------------------------------------------------------

Approximately half litre of peripheral blood was obtained from each of two anesthetized animals and their sera collected following standard procedures. Sera were precipitated using PEG, pellets suspended into 20 mL aliquots and passed through individual Sepharose CL-2B 100 mL columns. Results demonstrated that this escalation procedure yielded purified exosomes with the same NTA profile, SDS-PAGE and cryo-EM as those obtained from 2 mL aliquots of serum (Figure [4](#Fig4){ref-type="fig"}). Noticeably, the yield was significantly increased as proteins were detected by the Bradford assay in SEC fractions containing exosomes (Figure [4](#Fig4){ref-type="fig"}A) and NTA analysis revealed a twofold increase in the number of particles (10^10--11^ particles/mL) as opposed to those obtained from 2 mLs (10^8--9^ particles/mL). Last, PEG-precipitation did not affect the immunological properties of exosomes as immune sera similarly and specifically recognized them (Figure [4](#Fig4){ref-type="fig"}B).

Discussion {#Sec18}
==========

Here, for what we believe is the first time, we describe the isolation, characterization, antigenicity and scaling-up process of serum-derived exosomes from naïve pigs and from pigs actively or previously infected with PRRSV.

Firstly, size-exclusion chromatography was applied to analyze serum-derived exosomes from pigs in a small and scaling-up procedure. This single-standing methodology is presently considered a solid and reproducible method for isolation and characterization of extracellular vesicles in the size range of exosomes from different biological fluids such as plasma \[[@CR25], [@CR35]\], saliva \[[@CR36]\] and urine \[[@CR37]\]. In fact, it removes most contaminant abundant proteins and purifies 100--200 nm particles associated with classical exosomal markers. Accordingly, our results showed that exosomes eluted in fractions 7 to 10, whereas more abundant serum proteins (such as albumin), as judged by the Bradford assay, eluted in later fractions. Moreover, two "classical" exosomal markers, CD63 and CD81 \[[@CR38]\] showed maximum MFI values in these same fractions (Figures [1](#Fig1){ref-type="fig"}, [4](#Fig4){ref-type="fig"}), where high concentrations of particles in the size-range of exosomes were also detected by NTA and cryo-TEM analyses and low protein content was detected. Of interest, bicosome-like structures (vesicles within vesicles) were observed in agreement with similar structures found in structural studies from other fluids \[[@CR39]--[@CR41]\]. These results strongly suggest that porcine serum samples have similar and reproducible SEC elution profiles as described in human samples, reinforcing the use of SEC as a single-standing and easily implementing technology facilitating field studies of extracellular vesicles in animal diseases of veterinary importance.

To identify PRRSV viral proteins associated with serum-derived exosomes, we used nanoLC-MS/MS. Remarkably, RNA-dependent RNA polymerase, partial and nucleocapsid protein N, were detected only in exosomes from the non-viremic animals (Figure [2](#Fig2){ref-type="fig"}). The nucleocapsid protein (N) is one of the most abundant and immunodominant viral proteins during PRRS infection \[[@CR42]\]. This protein interacts with different cellular factors of the host to facilitate virus infection and its role is crucial for mature viral particle formation within the cell, binding to the viral RNA genome and replication machinery including RNA-dependent RNA polymerase, and also interacts with itself to form the core capsid \[[@CR43], [@CR44]\]. Of interest, the N protein and three non-structural (Nsps) PRRSV proteins have been identified as playing an important role in type I IFN suppression and modulation of the NF-kB pathway as it is translocated to the nucleus during early stages of infection \[[@CR43], [@CR45]\]. Late in infections, nucleocytoplasmic transport of the N protein increase the cytoplasmic concentration of this protein. It is tempting to speculate that an increase in virus N protein at cytoplasm during chronic infections might favor the release of the N-protein and RNA-dependent RNA polymerase in exosomes, which could at least partially explain the data from the proteomic analysis. In the absence of supporting data, this remains to be further demonstrated. Regardless, N proteins has been expressed in different models such as *Baculovirus* and *Escherichia coli* \[[@CR42]\] and soya been seeds \[[@CR46]\]; interestingly, in all cases it was capable of inducing both cellular and humoral immune response (murine model) or being recognized by PRRSV immune porcine sera.

To test the antigenic properties of serum-derived exosomes from previously infected animals, we first captured exosomes isolated from three non-viremic (NV) animals that were free of detectable virus (RT-PCR negative) at the time of sera collection. Analysis of serum-derived exosomes from V animals was not performed in sandwich ELISA as PRRSV virus has the same density and size of exosomes; thus, confounding such analyses. Immune sera from pigs previously exposed to PRRSV, specifically reacted to these exosomes in a dose-dependent manner and similar, albeit at lower values, to antigens contained in the Porcillis attenuated vaccine; these results thus demonstrate that viral proteins contained in the exosome preparation from NV animals are antigenic. The immunogenic properties of exosomes containing pathogen-associated antigens have been tested in several preclinical models and diseases \[[@CR18], [@CR19], [@CR47]\]. Yet, to the best of our knowledge, no reports are presently available on antigenic properties of serum-derived exosomes with no pathogen load detected in peripheral circulation. This observation may be of importance for future vaccine approaches.

As a *bonafide* aspect of these analyses, we present the first proteomics analysis of pig proteins contained in serum-derived exosomes (Additional file [2](#MOESM2){ref-type="media"}). More than 400 porcine proteins associated with lipid transport, response to external stimulus, response to stress, immune system processes, some enzymes and extracellular space proteins are enriched in our exosomal fractions indicating cargo-selection related to cell communication and metabolic processes. These proteins thus represent a first baseline proteome of porcine serum-derived exosomes facilitating future studies between host and pathogens in PRRSV and other animal diseases.

The use of nanovesicles in vaccine approaches against PRRSV is bringing new and recent exciting data. It has been previously reported that nanoparticle entrapped antigens are more effective than conventional vaccine platforms \[[@CR48]--[@CR50]\] and demonstrated increasing titers of virus neutralizing antibodies in serum and lungs. Additionally, a different kind of artificial exosome was used to deliver microRNA into porcine alveolar macrophages (PAMs) to suppress expression of CD163 or Sialoadhesin receptors in cell surface making those less susceptible to PRRSV infection and replication \[[@CR51]\]. Our results, including a scaling-up process, thus warrant further exploring serum-derived exosomes from PRRSV infections as a different vaccination approach. Regulatory aspects, similar to what has been recently positioned by the International Society of Extracellular Vesicles on human health \[[@CR52]\], should not encounter major obstacles in future animal trials.

Additional files {#Sec19}
================

10.1186/s13567-016-0345-x **Codification and status of virus in blood and antibodies in porcine sera samples received.** All samples were codified as soon as received in the laboratory and classified by virus and antibody status according to the RT-PCR and serology test for PRRSV.10.1186/s13567-016-0345-x **ELISA chessboard plate assay for standardization of NV, CN and V porcine sera immune recognition over inactivated viral particle PRRSV vaccine (Porcilis PRRS, Intervet).** Analyses of different dilutions of secondary antibody (A) 1/100, (B) 1/1000 (C) 1/10 000 and (D) 1/10 000 for each type of sera. Optical density (OD) was measured at 450nm and it is represented in the "Y" axis. "X" axis shows the dilution factor for sera samples (1/5 to 1/5000) and each bar represents a dilution for secondary antibody (1/100 to 1/100 000). The dilution used for further experiments was selected by comparison of differences between non-viremic and naïve samples and selecting the ones showing highest difference combined with highest dilution without signal saturation (1/50 for sera and 1/10 000 for secondary antibody).10.1186/s13567-016-0345-x **Naïve and viremic protein, FACS and nanosight profile. (A) (C) Viremic sample 201406-2PS (B) (D) Naïve sample 201406-CN2.** Viremic and naïve samples of sera were evaluated by the same methodology as non-viremic samples to detect any differences between groups. Protein and molecular markers profile were similar as already seen with non-viremic samples, where fractions enriched with exosomes exhibit higher MFI values for CD63 and CD81 even though there is no measurable protein detected by Bradford assay.10.1186/s13567-016-0345-x ***Sus scrofa*** **proteins identified by Maxquant/Andromeda analysis using nanoLC-MS/MS spectra.** Porcine proteins were identified in exosomes by proteomic analyses and several molecular markers of exosomes are present in these samples such as CD5, CD9, CD81 and CD63.10.1186/s13567-016-0345-x **Venn diagram of farm animal exosomal proteins and coincidence table comparing** ***Sus scrofa*** **and** ***Bos taurus***. Exosome proteins from different farm animal species obtained from Vesiclepedia were used to compare with our Sus scrofa exosomal proteins. Similarities among species in exosomal proteins are represented in the venn diagram.
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